{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:41:53Z","timestamp":1791423713713,"version":"4.3.3"},"reference-count":45,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006022","name":"French Ministry of Health via the Reference Center of Rare Pituitary Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgound<\/jats:title>\n                    <jats:p>The purpose of this study is to compare the effect of long-acting growth hormone (LAGH) to daily GH on body mass index (BMI) in children with growth hormone deficiency (GHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the PubMed database from its inception to July 2025 and identified three relevant randomized controlled trials lasting over 6 months, with extension phases providing longitudinal BMI data. Longitudinal BMI data were available for lonapegsomatropin, somatrogon, and somapacitan, but not for polyethylene glycol LAGH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 585 patients were included in the present analysis, of which 346 were in the LAGH group, and 239 were in the daily rhGH group, derived from seven original articles and two abstracts\/ePosters. At 12 months, there was a significant difference in BMI SD scores between LAGH and daily GH groups (Mean difference [MD] 0.66 SDS [95% confidence interval [CI] 0.04\u20131.29]). BMI SDS significantly increased in the LAGH group (MD + 0.41 SDS [95% CI 0.04\u20130.77] from 0 to 12 months), whereas it did not change in the daily GH group (MD \u22120.35 SDS [95% CI \u22120.76 to +0.07] from 0 to 12 months). Between 12 and 24 months, after switching from daily GH to LAGH (daily GH\/LAGH), or pursuing LAGH (LAGH\/LAGH) in the extension phases of the studies, BMI SDS significantly increased in the daily GH\/LAGH switching group (MD + 0.75 SDS [95% CI 0.24\u20131.27] from 12 to 24 months), whereas it remained steady in the LAGH\/LAGH group. Omitting one study at a time from the meta-analysis did not materially affect the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An increase in body mass index SD score is associated with the first year of LAGH use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag093","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:33:54Z","timestamp":1772541234000},"page":"1495-1502","source":"Crossref","is-referenced-by-count":10,"title":["Long-acting growth hormone for treating growth hormone deficiency in children: a meta-analysis of randomized controlled trials focusing on changes in body mass index"],"prefix":"10.1210","volume":"111","author":[{"given":"Lucie","family":"Levaillant","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology, University Hospital of Angers , 49000 Angers ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, University Hospital of Angers , 49000 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Bouhours-Nouet","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University Hospital of Angers , 49000 Angers ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, University Hospital of Angers , 49000 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Emeriau","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University Hospital of Angers , 49000 Angers ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, University Hospital of Angers , 49000 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Donzeau","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University Hospital of Angers , 49000 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University Hospital of Angers , 49000 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Hospices civils de Lyon , 69500 Bron ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, Hospices civils de Lyon , 69500 Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6527-805X","authenticated-orcid":false,"given":"Kevin","family":"Perge","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Hospices civils de Lyon , 69500 Bron ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, Hospices civils de Lyon , 69500 Bron ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Teinturier","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Bicetre University Hospital , 94270 Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, Bicetre University Hospital , 94270 Le Kremlin Bic\u00eatre, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Castets","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, La Timone Children\u2019s Hospital, APHM , 13385 Marseille ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, La Timone Children\u2019s Hospital, APHM , 13385 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Bicetre University Hospital , 94270 Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, Bicetre University Hospital , 94270 Le Kremlin Bic\u00eatre, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Reynaud","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, La Timone Children\u2019s Hospital, APHM , 13385 Marseille ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, La Timone Children\u2019s Hospital, APHM , 13385 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-4243","authenticated-orcid":false,"given":"Regis","family":"Coutant","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University Hospital of Angers , 49000 Angers ,","place":["France"]},{"name":"Reference Center for Rare Pituitary Diseases HYPO, University Hospital of Angers , 49000 Angers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"3","key":"2026042119582495200_dgag093-B1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1530\/EJE-11-0536","article-title":"Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics","volume":"165","author":"de Schepper","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026042119582495200_dgag093-B2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026042119582495200_dgag093-B3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2016-3776","article-title":"A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119582495200_dgag093-B4","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2016-3547","article-title":"Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children","volume":"102","author":"Zelinska","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119582495200_dgag093-B5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1515\/jpem-2022-0359","article-title":"An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment","volume":"36","author":"Zadik","year":"2023","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"2026042119582495200_dgag093-B6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-16-0905","article-title":"Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies","volume":"177","author":"Luo","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026042119582495200_dgag093-B7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40262-018-0662-5","article-title":"Pharmacokinetics and pharmacodynamics of once-weekly somapacitan in children and adults: supporting dosing rationales with a model-based analysis of three phase I trials","volume":"58","author":"Juul","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2026042119582495200_dgag093-B8","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial","volume":"105","author":"Savendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026042119582495200_dgag093-B9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/clinem\/dgaa775","article-title":"Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan","volume":"106","author":"Juul Kildemoes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026042119582495200_dgag093-B10","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1210\/clinem\/dgab529","article-title":"Weekly pegsomatropin in treatment-naive children with growth hormone deficiency: the phase 3 heiGHt trial","volume":"106","author":"Thornton","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026042119582495200_dgag093-B11","doi-asserted-by":"crossref","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","article-title":"Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study","volume":"107","author":"Deal","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026042119582495200_dgag093-B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000524600","article-title":"Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin(R)) in Japanese children with pediatric growth hormone deficiency: results from a randomized phase 3 study","volume":"95","author":"Horikawa","year":"2022","journal-title":"Horm Res Paediatr"},{"issue":"12","key":"2026042119582495200_dgag093-B13","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1210\/clinem\/dgac513","article-title":"Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial","volume":"107","author":"Miller","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119582495200_dgag093-B14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/clinem\/dgab928","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"107","author":"Savendahl","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026042119582495200_dgag093-B15","doi-asserted-by":"crossref","first-page":"e2680","DOI":"10.1210\/clinem\/dgac217","article-title":"Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results","volume":"107","author":"Maniatis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026042119582495200_dgag093-B16","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1210\/clinem\/dgad394","article-title":"Effective GH replacement with somapacitan in children with GHD: REAL4 2-year results and after switch from daily GH","volume":"108","author":"Miller","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026042119582495200_dgag093-B17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ejendo\/lvaf096","article-title":"Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4","volume":"192","author":"Miller","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026042119582495200_dgag093-B18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/cen.15025","article-title":"Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: results from REAL4, a phase 3 clinical trial","volume":"100","author":"Mori","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026042119582495200_dgag093-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000545786","article-title":"Somapacitan is effective and well tolerated in Chinese children with growth hormone deficiency: a randomized controlled phase 3 study","author":"Fu","year":"2025","journal-title":"Horm Res Paediatr"},{"issue":"jul21 1","key":"2026042119582495200_dgag093-B20","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"2026042119582495200_dgag093-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"2026042119582495200_dgag093-B22","author":"Centers for Disease Control"},{"key":"2026042119582495200_dgag093-B23","unstructured":"Coutant R . Coutant. Supplementary file 20260131. Figshare. Journal contribution. \u00a010.6084\/m9.figshare.31268725.v1"},{"key":"2026042119582495200_dgag093-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000545064","article-title":"Children with growth hormone deficiency treated with lonapegsomatropin demonstrated sustained height improvements for up to 6 years: enliGHten trial final results","author":"Maniatis","year":"2025","journal-title":"Horm Res Paediatr"},{"key":"2026042119582495200_dgag093-B25","author":"Maghnie"},{"key":"2026042119582495200_dgag093-B26","author":"Wajnrajch"},{"key":"2026042119582495200_dgag093-B27","doi-asserted-by":"crossref","first-page":"dgaf680","DOI":"10.1210\/clinem\/dgaf680","article-title":"Efficacy and safety of once-weekly lonapegsomatropin in adults with growth hormone deficiency: foresiGHt trial results","author":"Biller","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119582495200_dgag093-B28","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.110.RC4.5","article-title":"Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a phase 3 study","author":"Popovic","year":"2025","journal-title":"Endocrine Abstracts [Internet]"},{"issue":"4","key":"2026042119582495200_dgag093-B29","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026042119582495200_dgag093-B30"},{"issue":"2","key":"2026042119582495200_dgag093-B31","doi-asserted-by":"crossref","first-page":"bvaf001","DOI":"10.1210\/jendso\/bvaf001","article-title":"IGF-1 Assessment during weekly somatrogon treatment in pediatric patients with GH deficiency","volume":"9","author":"Nayak","year":"2025","journal-title":"J Endocr Soc"},{"issue":"11","key":"2026042119582495200_dgag093-B32","doi-asserted-by":"crossref","first-page":"bvad115","DOI":"10.1210\/jendso\/bvad115","article-title":"Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency","volume":"7","author":"Kildemoes","year":"2023","journal-title":"J Endocr Soc"},{"key":"2026042119582495200_dgag093-B33","doi-asserted-by":"crossref","first-page":"110919","DOI":"10.1016\/j.mce.2020.110919","article-title":"Effects of tissue-specific GH receptor knockouts in mice","volume":"515","author":"List","year":"2020","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2026042119582495200_dgag093-B34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev"},{"issue":"3","key":"2026042119582495200_dgag093-B35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bjp.2008.153","article-title":"Regulation of muscle mass by growth hormone and IGF-I","volume":"154","author":"Velloso","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2026042119582495200_dgag093-B36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/EJE-20-0325","article-title":"Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome","volume":"184","author":"Bang","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026042119582495200_dgag093-B37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5603\/EP.a2018.0074","article-title":"Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation\u2014first three years of Polish experience","volume":"70","author":"Petriczko","year":"2019","journal-title":"Endokrynol Pol"},{"issue":"8804","key":"2026042119582495200_dgag093-B38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/0140-6736(92)91594-X","article-title":"Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with laron-type dwarfism","volume":"339","author":"Laron","year":"1992","journal-title":"The Lancet"},{"issue":"s399","key":"2026042119582495200_dgag093-B39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1651-2227.1994.tb13306.x","article-title":"Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analogue: preliminary results","volume":"399","author":"Martinez","year":"1994","journal-title":"Acta Paediatr Suppl"},{"issue":"1","key":"2026042119582495200_dgag093-B40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ghir.2005.12.001","article-title":"Long-term IGF-I treatment of children with laron syndrome increases adiposity","volume":"16","author":"Laron","year":"2006","journal-title":"Growth Horm IGF Res"},{"issue":"1-2","key":"2026042119582495200_dgag093-B41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/07435800.2018.1493598","article-title":"Growth hormone therapy in children with idiopathic short stature\u2014the effect on appetite and appetite-regulating hormones: a pilot study","volume":"44","author":"Yackobovitch-Gavan","year":"2019","journal-title":"Endocr Res"},{"issue":"4","key":"2026042119582495200_dgag093-B42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/obr.12362","article-title":"Family-based interventions to increase physical activity in children: a systematic review, meta-analysis and realist synthesis","volume":"17","author":"Brown","year":"2016","journal-title":"Obes Rev"},{"key":"2026042119582495200_dgag093-B43","author":"Food and Drug Administration"},{"key":"2026042119582495200_dgag093-B44","author":"Food and Drug Administration"},{"key":"2026042119582495200_dgag093-B45","author":"Food and Drug Administration"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag093\/67253865\/dgag093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag093\/67253865\/dgag093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag093\/67253865\/dgag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:58:36Z","timestamp":1776815916000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/5\/1495\/8508630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag093","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,5]]}}}